Literature DB >> 34329372

Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?

Ana Jiménez-Ubieto1, Bruno Paiva2, Noemi Puig3, Maria-Teresa Cedena1, Joaquín Martínez-López1, Albert Oriol4, María-Jesús Blanchard5, Rafael Ríos6, Jesús Martin7, Rafael Martínez8, Anna Sureda9, Miguel-Teodoro Hernández10, Javier de la Rubia11, Isabel Krnisk12, Valentín Cabañas13, Luis Palomera14, José María Sánchez-Pina1, Joan Bargay15, María-Victoria Mateos3, Laura Rosiñol16, Joan Blade16, Jesús San Miguel2, Juan José Lahuerta1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34329372     DOI: 10.1182/blood.2021012319

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  2 in total

1.  Tumor Reduction in Multiple Myeloma: New Concepts for New Therapeutics.

Authors:  Rafael Alonso; Juan José Lahuerta
Journal:  Front Oncol       Date:  2022-01-14       Impact factor: 6.244

2.  Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.

Authors:  Noemí Puig; María-Teresa Contreras; Cristina Agulló; Joaquín Martínez-López; Albert Oriol; María-Jesús Blanchard; Rafael Ríos; Jesús Martín; María-Belén Iñigo; Anna Sureda; Miguel-Teodoro Hernández; Javier de la Rubia; Verónica González-Calle; Isabel Krsnik; Valentín Cabañas; Luis Palomera; José-María Moraleda; Joan Bargay; María-Teresa Cedena; Bruno Paiva; Laura Rosiñol; Joan Bladé; Jesús San Miguel; Juan-José Lahuerta; María-Victoria Mateos
Journal:  Blood Adv       Date:  2022-06-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.